These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

617 related items for PubMed ID: 31766077

  • 1. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.
    Li Z, Li P, Yan B, Gao Q, Jiang X, Zhan Z, Yan Q, Lizaso A, Huang C.
    Thorac Cancer; 2020 Jan; 11(1):176-180. PubMed ID: 31766077
    [Abstract] [Full Text] [Related]

  • 2. Leptomeningeal recurrence after long-term alectinib therapy for non-small cell lung cancer harboring an EML4-ALK fusion protein.
    Kawamura T, Murakami H, Kobayashi H, Nakashima K, Omori S, Wakuda K, Ono A, Kenmotsu H, Naito T, Endo M, Takahashi T.
    Invest New Drugs; 2019 Feb; 37(1):184-187. PubMed ID: 29971546
    [Abstract] [Full Text] [Related]

  • 3. Successful treatment with lorlatinib in a patient with meningeal carcinomatosis of ALK-positive non-small cell lung cancer resistant to alectinib and brigatinib: A case report.
    Nakashima K, Demura Y, Kurokawa K, Takeda T, Jikuya N, Oi M, Tada T, Akai M, Ishizuka T.
    Medicine (Baltimore); 2021 Oct 01; 100(39):e27385. PubMed ID: 34596160
    [Abstract] [Full Text] [Related]

  • 4. Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient.
    Ge FJ, Dai XY, Qiu Y, Liu XN, Zeng CM, Xu XY, Chen YD, Zhu H, He QJ, Gai RH, Ma SL, Chen XQ, Yang B.
    Acta Pharmacol Sin; 2024 Jun 01; 45(6):1252-1263. PubMed ID: 38360931
    [Abstract] [Full Text] [Related]

  • 5. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
    Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, Müller B, Shaw AT.
    J Thorac Oncol; 2019 Jul 01; 14(7):1233-1243. PubMed ID: 30902613
    [Abstract] [Full Text] [Related]

  • 6. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.
    Gainor JF, Sherman CA, Willoughby K, Logan J, Kennedy E, Brastianos PK, Chi AS, Shaw AT.
    J Thorac Oncol; 2015 Feb 01; 10(2):232-6. PubMed ID: 25526238
    [Abstract] [Full Text] [Related]

  • 7. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH.
    Lancet Oncol; 2014 Sep 01; 15(10):1119-28. PubMed ID: 25153538
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).
    Isozaki H, Hotta K, Ichihara E, Takigawa N, Ohashi K, Kubo T, Ninomiya T, Ninomiya K, Oda N, Yoshioka H, Ichikawa H, Inoue M, Takata I, Shibayama T, Kuyama S, Sugimoto K, Harada D, Harita S, Sendo T, Tanimoto M, Kiura K.
    Clin Lung Cancer; 2016 Nov 01; 17(6):602-605. PubMed ID: 27405684
    [Abstract] [Full Text] [Related]

  • 13. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
    Lai Y, Kacal M, Kanony M, Stukan I, Jatta K, Kis L, Norberg E, Vakifahmetoglu-Norberg H, Lewensohn R, Hydbring P, Ekman S.
    Biochem Biophys Res Commun; 2019 Apr 02; 511(2):260-265. PubMed ID: 30791979
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.
    Guo W, Liang J, Zhang D, Huang X, Lv Y.
    Medicine (Baltimore); 2022 Oct 07; 101(40):e30913. PubMed ID: 36221356
    [Abstract] [Full Text] [Related]

  • 16. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G, Seto T.
    Respir Investig; 2014 Nov 07; 52(6):330-8. PubMed ID: 25453376
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial.
    Harada D, Isozaki H, Kozuki T, Yokoyama T, Yoshioka H, Bessho A, Hosokawa S, Takata I, Takigawa N, Hotta K, Kiura K, Okayama Lung Cancer Study Group.
    Thorac Cancer; 2021 Mar 07; 12(5):643-649. PubMed ID: 33470536
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.